A path to translation: How 3D patient tumor avatars enable next generation precision oncology

Shree Bose; Margarida Barroso; Milan G Chheda; Hans Clevers; Elena Elez; Salma Kaochar; Scott E Kopetz; Xiao-Nan Li; Funda Meric-Bernstam; Clifford A Meyer; Haiwei Mou; Kristen M Naegle; Martin F Pera; Zinaida Perova; Katerina A Politi; Benjamin J Raphael; Paul Robson; Rosalie C Sears; Josep Tabernero; David A Tuveson; Alana L Welm; Bryan E Welm; Christopher D Willey; Konstantin Salnikow; Jeffrey H Chuang; Xiling Shen

doi:10.1016/j.ccell.2022.09.017

A path to translation: How 3D patient tumor avatars enable next generation precision oncology

Cancer Cell. 2022 Dec 12;40(12):1448-1453. doi: 10.1016/j.ccell.2022.09.017. Epub 2022 Oct 20.

Authors

Shree Bose¹, Margarida Barroso², Milan G Chheda³, Hans Clevers⁴, Elena Elez⁵, Salma Kaochar⁶, Scott E Kopetz⁷, Xiao-Nan Li⁸, Funda Meric-Bernstam⁹, Clifford A Meyer¹⁰, Haiwei Mou¹¹, Kristen M Naegle¹², Martin F Pera¹³, Zinaida Perova¹⁴, Katerina A Politi¹⁵, Benjamin J Raphael¹⁶, Paul Robson¹⁷, Rosalie C Sears¹⁸, Josep Tabernero⁵, David A Tuveson¹⁹, Alana L Welm²⁰, Bryan E Welm²¹, Christopher D Willey²², Konstantin Salnikow²³, Jeffrey H Chuang²⁴, Xiling Shen²⁵

Affiliations

¹ Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27708, USA.
² Department of Molecular and Cellular Physiology, Albany Medical College, Albany, NY 12208, USA.
³ Department of Medicine, Washington University in St. Louis, St. Louis, MO, 63110 USA.
⁴ Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, Uppsalalaan 8, Utrecht, 3584 CT, Netherlands; Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Roche Pharma, Basel, Switzerland.
⁵ Vall d'Hebron Hospital Campus and Institute of Oncology, International Oncology Bureau-Quiron, University of Vic-Central University of Catalonia, Barcelona, 08035 Spain.
⁶ Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
⁷ The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
⁸ Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA.
⁹ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
¹⁰ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27708, USA.
¹¹ The Wistar Institute, Philadelphia, PA 19104, USA.
¹² Department of Biomedical Engineering and the Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22903, USA.
¹³ The Jackson Laboratory, Bar Harbor, ME 04660, USA.
¹⁴ European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
¹⁵ Departments of Pathology and Internal Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT 06510, USA.
¹⁶ Department of Computer Science, Princeton University, Princeton, NJ 08540, USA.
¹⁷ The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA; Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT 06032, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA.
¹⁸ Department of Medical and Molecular Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
¹⁹ Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
²⁰ Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
²¹ Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
²² Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
²³ Division of Cancer Biology, National Cancer Institute, NIH, Rockville, MD 20850, USA. Electronic address: salnikok@mail.nih.gov.
²⁴ The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA; Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, CT 06032, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA. Electronic address: jeff.chuang@jax.org.
²⁵ Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA. Electronic address: xiling.shen@terasaki.org.

Abstract

3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Humans
Medical Oncology
Neoplasms* / diagnosis
Neoplasms* / genetics
Neoplasms* / therapy
Precision Medicine
Prospective Studies

Abstract

Publication types

MeSH terms

Grants and funding